Antonelli, Flaminia
 Distribuzione geografica
Continente #
NA - Nord America 173
EU - Europa 109
AS - Asia 69
AF - Africa 6
Totale 357
Nazione #
US - Stati Uniti d'America 172
IT - Italia 28
SG - Singapore 26
SE - Svezia 21
CN - Cina 20
IE - Irlanda 17
ID - Indonesia 13
DE - Germania 8
GB - Regno Unito 8
FI - Finlandia 7
RU - Federazione Russa 7
IN - India 6
CI - Costa d'Avorio 5
FR - Francia 4
NL - Olanda 3
BE - Belgio 2
HK - Hong Kong 2
AT - Austria 1
CH - Svizzera 1
HU - Ungheria 1
IL - Israele 1
JP - Giappone 1
ME - Montenegro 1
PA - Panama 1
SC - Seychelles 1
Totale 357
Città #
Chandler 45
Ashburn 29
New York 24
Dublin 16
Singapore 16
Jakarta 13
Chicago 12
Milan 12
Beijing 7
Bremen 6
Abidjan 5
Helsinki 5
Pune 5
Moscow 4
Rome 4
Amsterdam 3
Bologna 3
London 3
Ragusa 3
Southampton 3
Boardman 2
Boydton 2
Brussels 2
Edinburgh 2
Hong Kong 2
Lappeenranta 2
Nuremberg 2
Paris 2
White Salmon 2
Anchorage 1
Andover 1
Anniston 1
Besançon 1
Boston 1
Bracke 1
Budapest 1
Busto Arsizio 1
Catania 1
Dresden 1
Kochi 1
Los Angeles 1
Marseille 1
Panama City 1
Piansano 1
Podgorica 1
Princeton 1
Tokyo 1
Vienna 1
Washington 1
Wenzhou 1
Zurich 1
Totale 258
Nome #
Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients 58
Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa 44
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 39
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 38
Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study 33
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 32
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 26
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? 24
Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment 19
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study 17
Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis 16
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation 13
Infectious adverse events in patients with atopic dermatitis treated with baricitinib 7
Totale 366
Categoria #
all - tutte 2.768
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.768


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20227 0 0 0 0 0 0 0 0 0 3 2 2
2022/2023161 3 21 12 21 11 14 8 20 28 13 9 1
2023/2024170 2 25 14 26 14 33 9 3 6 8 18 12
2024/202528 5 1 22 0 0 0 0 0 0 0 0 0
Totale 366